Michael Kotsanis

Michael Kotsanis

Chief Executive Officer at ACRUX LIMITED

Health Technology
Consumer Services
Commercial Services

Profile

Michael John Kotsanis is currently the Chief Executive Officer, Director & MD at Acrux Ltd.
and a Director at AI Lamb (NZ) Ltd.
He previously worked as an Independent Non-Executive Director at Idt Australia Ltd., Chief Commercial Officer & Director at Synthon Holding BV, President-Europe, Middle East & Africa at Hospira Adelaide Pty Ltd., President-Asia Pacific at Mayne Pharma Ltd., and Vice President at Hospira Australia Pty Ltd.
He also served as a Director at the Generic Medicines Industry Association Pty Ltd.
and Medicines For Europe.
Mr. Kotsanis received his undergraduate degree from Monash University and his graduate degree from the University of Technology Sydney.

Michael Kotsanis active positions

CompaniesPositionStart
ACRUX LIMITED Chief Executive Officer 2014-11-02
Director/Board Member 2020-11-25
All active positions of Michael Kotsanis

Former positions of Michael Kotsanis

CompaniesPositionEnd
IDT AUSTRALIA LIMITED Director/Board Member 2022-11-27
Director/Board Member 2014-09-30
Corporate Officer/Principal 2010-05-31
Corporate Officer/Principal 2006-08-31
Corporate Officer/Principal -
See the detail of Michael Kotsanis's experience

Training of Michael Kotsanis

Monash University Undergraduate Degree
University of Technology Sydney Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Kotsanis's experience

Connections

40

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
ACRUX LIMITED

Health Technology

IDT AUSTRALIA LIMITED

Health Technology

Private companies7

Health Technology

Health Technology

Commercial Services

Commercial Services

Medicines For Europe

Health Technology

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Michael Kotsanis
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW